Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Biotechnology Sector Holding Up Well In Sell-Off 0 comments
    Jun 21, 2012 2:23 PM | about stocks: XBI, ONXX, LGND, MDVN

    We have been at BIO 2012 in Boston over the past week and will provide interesting trends and data from the Meeting by Monday.

    Global Slowdown Fears: Market off 1.5% at mid-day with the NASDAQ off 1.7%

    The bimodal market has lost its zing from last week due to continued worries from Europe especially Spanish banks, a weak Euro($1.25), continued concern about global growth as evidenced by crude dropping below $80 to $79.22, job outlook weak and although the FED still has an easing bias appears to have run out weapons as more QE is not on the table. The FED has provided plenty of liquidity but it is not going to the people who need it. Gold is being crushed down $44 off 2.74% and is discouraging traders as the printing presses are on hold and inflation is low. Technical levels are being broken on gold. Silver is down 5%.To exacerbate the sell-off Goldman Sachs put out a sell on the S&P targeting the 1285 level near term which would be at June 1 lows but still up YTD.

    Biotechnology Sector Gets Good Clinical News Boost

    The biotech sector remains resilient off only 0.78% IBB ($127.33), up 22% YTD! The XBI ($86.44) is outperforming the sector today up 0.48% and a new high for the year. Among the XBI holdings are AMLN ONXX PCYC REGN VRTX. all recent big movers.

    The Rayno Life Science Portfolio also had some big winners YTD like ALXN, BIIB, GPRO, REGN SGEN but is weak today particularly diagnostics and tools which correlate more with the general economy.

    The big news today was Onyxx (ONXX $63.92) Pharmaceuticals which soared 43% up $19.33 with the FDA Oncologic Drugs Advisory Committee (ODAC) receiving a positive vote on carfilzomid (Kyprolis) for multiple myeloma across a variety of treatment lines. The Company has a robust pipeline of cancer drugs and with a market cap of $4.1B is on a short list of potential acquisitions by big pharma. Development partner Ligand (LGND $17.11) was also up $2.55 on the news.

    Celgene (CELG $59.70) was on the downside 11.11% on news that it pulled its European application for wider use of its blood cancer drug Revlimid.On June 17 RBC Capital markets downgraded the drug to "sector perform".

    Our mid-cap biopharmaceutical index is mixed with some winners but more red than green. Our paired trade recommendation from June 8 short MDVN ($89.50) long PCYC ($46.25) is working with PCYC outperforming by 26%. We thought the clinical portfolio of Pharmacyclics offered more upside than Medivation and used the MDVN short as hedge on market risk.

    Disclosure: I am short MDVN.

    Additional disclosure: Using MDVN as a short hedge on biotech sector

    Stocks: XBI, ONXX, LGND, MDVN
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.